Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.35 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30772359 | 0.90 | HTR2A (0.38) | HTR2ASLC6A4KCNH2P2RX7SLC6A2 | |
| SCHEMBL30772375 | 0.88 | HTR2A (0.38) | HTR2ASLC6A4KCNH2P2RX7SLC6A2 | |
| SCHEMBL31448529 | 0.82 | P2RX7 (0.34) | HTR2ASLC6A4KCNH2P2RX7SMN1; SMN2 | |
| SCHEMBL31448553 | 0.80 | SMN1; SMN2 (0.43) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31448458 | 0.78 | SLC6A2 (0.38) | HTR2ASLC6A4KCNH2P2RX7SLC6A2 | |
| SCHEMBL31448459 | 0.73 | HTR2A (0.34) | HTR2ASLC6A4KCNH2P2RX7 | |
| SCHEMBL30772347 | 0.72 | SLC6A4 (0.37) | HTR2ASLC6A4KCNH2CLCN2SLC6A2 | |
| SCHEMBL31448418 | 0.71 | TAAR1 (0.42) | HTR2A | |
| SCHEMBL31448554 | 0.70 | SLC6A4 (0.35) | HTR2ASLC6A4KCNH2P2RX7SLC6A2 | |
| SCHEMBL31448577 | 0.70 | L3MBTL1 (0.39) | NPC1RAB9AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| EP-4512801-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | Kissei Pharmaceutical Co., Ltd. (JP) | 2025-02-26 | — | — | EP | disclosed |
| CN-119343332-A | 3, 4-Dihydro-quinolin-2 (1H) -one compounds | 橘生药品工业株式会社 | 2025-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361210-A1 | 3,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND | TSHR, TRHR, GHSR | HTR2A 1033/4885SLC6A4 1932/4885KCNH2 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.